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the fact that neddylated p53 can also be ubiquitinated,
it is possible that neddylated p53 may also undergo
proteasome-mediated degradation in certain situations,
negating a need for regulated deneddylation. Clearly,
understanding the dynamic relationship between p53
neddylation, p53 ubiquitination, and p53 turnover will
be required to determine how neddylation fits into the
p53 degradation pathway.
As is often the case with novel findings, this work
raises as many questions as it answers. In particular,
it is not clear under what physiological settings p53
neddylation occurs, nor is it evident precisely how ned-
dylation regulates p53 function. Does neddylation play
a critical role overall in p53 biology or is it a minor compo-
nent of p53’s diverse regulatory apparatus? In addition,
this work raises the question of whether Nedd8 transfer
through RING-based E3s is a frequent event. If Mdm2
is a harbinger of things to come, then there could be
many more RING-based E3s that are capable of func-
tioning together with Ubc12 to promote neddylation of
proteins that are otherwise targets of a RING-based
ubiquitin ligase activity. If this is the case, then an inter-
mingling of neddylation and ubiquitination could be the
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Figure 1. Nedd8 Conjugation Pathways
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damage. DNA damage-dependent phosphorylation
blocks association with Mdm2 with p53 (Yang et al.,
2004) and, based on mutagenesis experiments (Xirodi-
mas et al., 2004), would presumably block neddylation
as well. An additional question concerns removal of Huntington’s Disease:
Nedd8. In SCF complexes, Nedd8 is removed by the
New Paths to Pathogenesisaction of the COP9 complex (Cope and Deshaies, 2003).
How and under what circumstances Nedd8 is removed
from p53 is unknown, although at long times after DNA
damage, the levels of neddylated p53 were reduced
while total p53 levels remained high, suggesting the Huntington’s disease is a progressive autosomal dom-
inant neurodegenerative disorder caused by expan-existence of a deneddylation pathway. However, given
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sion of a CAG repeat coding for polyglutamine in the heterozygous knockouts are normal, but early loss of
huntingtin expression to between 0% to 50% of normalhuntingtin protein. A recent report (Gauthier et al.,
2004, this issue of Cell) suggests a new mechanism has severe neurodevelopmental effects. However, these
findings do not exclude a role for a slowly developinginvolving altered interactions with a protein involved
in axonal transport, leading to loss of neurotrophic late-life loss of huntingtin function in disease pathogene-
sis. In the present study, mutant huntingtin has an effectfactor transport. This suggests an intriguing conver-
gence to previously described pathways implicating similar to inhibiting wild-type huntingtin with RNA inter-
ference, suggesting a loss-of-function or dominant-neg-neurotrophin transcription in HD pathogenesis.
ative mechanism. This loss-of-function mechanism then
would complement the previous gain-of-function mech-
anism originally described by Saudou et al. (1998).While many huntingtin protein interactors have been
described (Harjes and Wanker, 2003), and a number of Whether this kind of a loss-of-function mechanism is
relevant to disease pathogenesis still needs to be dem-mechanisms linking these interactors to HD pathogene-
sis—including alteration in gene transcription, activation onstrated.
A related issue is the question of protein aggregation.of apoptosis, metabolic poisoning, or blockage of axo-
nal transport—have been proposed, the role of hunting- There is a striking correspondence between the polyglu-
tamine length threshold for disease and the polygluta-tin interacting proteins in the disease has remained elu-
sive. The group led by Frederick Saudou (Gauthier et mine length at which huntingtin aggregates, though the
relationship among aggregation, inclusions, and dis-al., 2004) now describes functional consequences of the
interaction between huntingtin and huntingtin-associ- ease remains controversial (Ross and Poirier, 2004). Pre-
vious studies had suggested that mutant huntingtinated protein 1 (HAP1). HAP1 was the first huntingtin
interactor identified, and it in turn interacts with proteins could also block axonal transport via purely mechanical
effects of aggregates (Feany and La Spada, 2003). Ininvolved in vesicle transport, including the p150Glued sub-
unit of dynactin. The current study provides evidence the current study, no aggregates were detected using
light microscopy, suggesting effects due to mutant hunt-that huntingtin enhances vesicle transport of brain-
derived neurotrophic factor (BDNF) along microtubules. ingtin monomers or perhaps small oligomeric assem-
blies.BDNF transport was attenuated by reducing the levels
of wild-type huntingtin, or by the introduction of mutant A third issue is the cellular location of toxic effects.
Most (though not all) previous studies have suggestedhuntingtin. The alteration of the complex of huntingtin,
HAP1, and P150Glued correlated with reduced association that nuclear localization of mutant huntingtin enhances
toxicity, as Saudou et al. initially observed (1998). It isof motor proteins with microtubules. The loss of BDNF
transport appeared to be associated with reduced neu- suggested in the discussion of the current study that
neuronal dysfunction due to interference with neuro-rotrophic support and cell toxicity.
Previous cell culture and conditional knockout mouse trophin transport (a cytoplasmic effect) might be a pre-
cursor to later neuronal cell death.studies have suggested a different mechanism for the
effect of huntingtin on BDNF, involving a neuroprotec- A fourth issue is the relevance of proteolytic cleavage
(DiFiglia, 2002). It has been proposed that huntingtintive role for huntingtin (Trottier and Mandel, 2001; Catta-
neo et al., 2001), mediated through enhancement of can undergo proteolytic cleavage, generating a toxic
fragment, which may be transported to the nucleus.BDNF gene transcription by normal huntingtin in the
nucleus. Additionally, mutant huntingtin may affect However, in the current model, full-length mutant hunt-
ingtin interferes with BDNF transport, while truncatedBDNF transcription by altering the transcriptional activi-
ties of CBP, Sp1, TAF130, and other molecules, presum- mutant huntingtin does not.
A fifth issue relates to whether cell death in HD is cellably via a gain-of-function mechanism (Sugars and
Rubinsztein, 2003). The new study complements this pre- autonomous or might involve cell interactions, or as it is
sometimes put, “murder vs. suicide.” In cell expressionvious work by suggesting that, in addition to actions on
BDNF transcription, huntingtin may also regulate BDNF studies, it would appear that mutant huntingtin could
be toxic in a cell autonomous fashion. However, it istransport and activity (Figure 1).
The current study also complements the previous possible that cell interactions are relevant in vivo. Inter-
estingly, BDNF can be transported to the striatum viaseminal study by Saudou et al. (1998), which demon-
strated that N-terminal mutant huntingtin fragments tar- cortico-striatal axon projections. Furthermore HAP1 in-
teracts not just with components of retrograde transportgeted to the nucleus cause neuronal toxicity via a gain-
of-function mechanism. Considered together, these two motors such as dynactin, but also with components of
anterograde transport machinery. Thus, it is conceivablestudies raise in a new form many of the overarching
questions in the field of polyglutamine disease mecha- that huntingtin interference with BDNF transport could
relate to the depletion of BDNF seen in HD striatum.nisms (Ross, 2002; Tobin and Signer, 2000).
One question relates to gain versus loss-of-function There may be other effects of aberrant neurotrophic
support. Previous studies by DiFiglia’s group suggesteffects. As a disease with almost pure genetic domi-
nance, HD has often been presumed to result from a that HD may involve not just neuronal degeneration but
also changes which appear to be attempts at neu-gain of a toxic function. Loss-of-function mechanisms
(perhaps as dominant-negatives via polyglutamine inter- ronal regeneration.
This brings up the related issue of anatomic specific-actions) have also been proposed. A pure loss-of-func-
tion mechanism appears unlikely. Homozygous hunt- ity. While polyglutamine expansion diseases share many
pathological features, the exact distributions of neuronsingtin knockouts are embryonic lethals. Furthermore
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Figure 1. Model for HD Cellular Pathogenesis Involving Both Cytoplasmic and Nuclear Effects on BDNF
Huntingtin is normally predominantly cytoplasmic. One of its normal functions involves regulation of vesicle transport, including transport of
BDNF. It may play a role in the regulation of gene transcription in the nucleus, especially for neurotrophic molecules such as BDNF. The
mutation causes a conformational change and abnormal folding of the protein, which can be corrected by molecular chaperones. Mutant
huntingtin has effects both in the cytoplasm and in the nucleus. In the cytoplasm, full-length mutant huntingtin can interfere with BDNF
vesicular transport on microtubules. Mutant huntingtin can also undergo proteolytic cleavage, both in the cytoplasm and in the nucleus (shown
here as taking place only in the cytoplasm for simplicity), which may involve several steps. The N terminus with the expanded repeat can
assume a  sheet structure. Toxicity in the cytoplasm may involve soluble monomers or oligomers or possibly insoluble aggregates, via
inhibition of the proteasome or activation of caspases directly or via mitochondrial effects. Cytoplasmic aggregates accumulate in perinuclear
or neuritic regions and are ubiquitinated. Neuritic aggregates can interfere with BDNF transport by mechanical disruption. The mutant protein
translocates to the nucleus, where it forms intranuclear inclusions, though they are not primarily responsible for toxicity. Nuclear toxicity is
believed to be caused by interference with gene transcription, leading to loss of transcription of neuroprotective molecules such as BDNF.
that degenerate differ among the diseases. The effects of these new pathways to pathogenesis should lead to
new approaches to rational therapeutics.described in the current study are likely not to be general
events for polyglutamine pathogenesis, but could ex-
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